Literature DB >> 3723582

An in-vitro model of colonisation resistance to Clostridium difficile infection.

S P Borriello, F E Barclay.   

Abstract

To investigate the importance of the normal gut flora in preventing the establishment of Clostridium difficile in vivo we have developed an in-vitro test system based on growth in faecal emulsions. Growth of C. difficile and cytotoxin production are inhibited in faecal emulsions from healthy adults, but not in sterilised emulsions; the importance of viable bacteria in the inhibitory system is evident. Generally, faecal emulsions derived from infants, children and geriatric patients were less inhibitory than those from healthy adults. Those from bottle-fed infants were significantly less inhibitory than those from breast-fed infants. Decreased levels of cytotoxin in the latter group were attributed to the acidic pH of the stools. With the different patient groups studied, faecal samples not inhibitory to C. difficile in vitro were obtained from 21% of patients with antibiotic-associated diarrhoea, 33% of those taking antibiotics but who did not have diarrhoea, 18.7% of those with diarrhoea unassociated with antibiotics, and 79% of those with C. difficile-mediated diarrhoea. In some cases inhibition was due to low faecal pH, as in some infants, and in others to other filterable substances. The degree of inhibition could not be linked to specific volatile fatty acids or enzymes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3723582     DOI: 10.1099/00222615-21-4-299

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  37 in total

1.  Asymptomatic carriage of Clostridium difficile in patients with cystic fibrosis.

Authors:  S L Peach; S P Borriello; H Gaya; F E Barclay; A R Welch
Journal:  J Clin Pathol       Date:  1986-09       Impact factor: 3.411

2.  Vancomycin Treatment Alters Humoral Immunity and Intestinal Microbiota in an Aged Mouse Model of Clostridium difficile Infection.

Authors:  Edward van Opstal; Glynis L Kolling; John H Moore; Christine M Coquery; Nekeithia S Wade; William M Loo; David T Bolick; Jae Hyun Shin; Loren D Erickson; Cirle A Warren
Journal:  J Infect Dis       Date:  2016-02-24       Impact factor: 5.226

3.  Clostridium difficile infection in older adults.

Authors:  Robin Lp Jump
Journal:  Aging health       Date:  2013-08-01

4.  Clostridium difficile infection of the gut.

Authors:  A P Dodson; S P Borriello
Journal:  J Clin Pathol       Date:  1996-07       Impact factor: 3.411

5.  Clostridium difficile: a pathogen of the nineties.

Authors:  T V Riley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-03       Impact factor: 3.267

Review 6.  The Intersection Between Colonization Resistance, Antimicrobial Stewardship, and Clostridium difficile.

Authors:  Rossana Rosa; Curtis J Donskey; L Silvia Munoz-Price
Journal:  Curr Infect Dis Rep       Date:  2018-06-07       Impact factor: 3.725

7.  Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea.

Authors:  Vijay C Antharam; Eric C Li; Arif Ishmael; Anuj Sharma; Volker Mai; Kenneth H Rand; Gary P Wang
Journal:  J Clin Microbiol       Date:  2013-06-26       Impact factor: 5.948

Review 8.  Clostridium difficile: its disease and toxins.

Authors:  D M Lyerly; H C Krivan; T D Wilkins
Journal:  Clin Microbiol Rev       Date:  1988-01       Impact factor: 26.132

9.  Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects.

Authors:  Alexander G Vandell; Satoshi Inoue; Justin Dennie; Yasuo Nagasawa; Roohi Gajee; Joe Pav; George Zhang; Cynthia Zamora; Nobuhisa Masuda; Giorgio Senaldi
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

Review 10.  Epidemiology, Diagnosis, and Management of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease.

Authors:  Krishna Rao; Peter D R Higgins
Journal:  Inflamm Bowel Dis       Date:  2016-07       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.